Abstracts tagged "Infection"

Abstract Number: 1999 • 2012 ACR/ARHP Annual Meeting
Immunogenicity and Safety of Two Doses of Influenza A H1N1⁄2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old
Guilherme Trudes¹, Nadia E. Aikawa², Lucia M. Campos³, Rosa M.R. Pereira⁴, Julio C. B. Moraes⁵, Ana Cristina Ribeiro⁶, Joao Miraglia⁷, Maria do Carmo S. Timenetsky⁸, Eloisa Bonfa⁴ and Clovis Artur Silva⁹, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Pediatric Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Rheumatology Divison, University of Sao Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Instituto Butantan, Fundação Butantan, São Paulo, Brazil, ⁸Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In 2010 the Advisory Committee on Immunization Practices from the CDC recommended that all children should receive the trivalent seasonal influenza vaccine containing the…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Renata Baronaite Hansen¹ and Søren Jacobsen², ¹Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…
Abstract Number: 1424 • 2012 ACR/ARHP Annual Meeting
Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)
José M. Pego-Reigosa¹, Íñigo Rúa-Figueroa², Francisco J. López-Longo³, María Galindo⁴, Jaime Calvo-Alén⁵, Alejandro Olivé⁶, Loreto Horcada⁷, Esther Uriarte⁸, Eva Tomero⁹, Ana Sánchez-Atrio¹⁰, Carlos Montilla¹¹, José Rosas¹², Antonio Fernández-Nebro¹³, Paloma Vela¹⁴, Mercedes Freire¹⁵, Lucía Silva¹⁶, Elvira Díez-Álvarez¹⁷, Carlos Marras¹⁸, Antonio Zea¹⁹, Javier Narváez²⁰, Jose Luis Marenco²¹, Monica Fernández de Castro²², Olaia Fernánde-Berrizbeitia²³, Marian Gantes²⁴ and Celia Erausquin²⁵, ¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ²Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ⁵Reumatología, Hospital Sierrallana, Torrelavega, Spain, ⁶Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Reumatología, Hospital de Navarra, Spain, ⁸Reumatología, Hospital de Donosti, Donosti, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Reumatología, Hospital Príncipe de Asturias, Madrid, Spain, ¹¹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Reumatología, Hospital de Marina Baixa, Alicante, Spain, ¹³Reumatología, Hospital Carlos Haya, Malaga, Spain, ¹⁴Reumatología, Hospital General de Alicante, Alicante, Spain, ¹⁵Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Rheumatology, Hospital de Guadalajara, Guadalajara, Spain, ¹⁷Reumatología, Hospital de León, León, Spain, ¹⁸Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁹Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁰Reumatología, Hospital de Bellvitge, Barcelona, Spain, ²¹Rheumatology, Hospital de Valme, Seville, Spain, ²²Hospital Puerta del Hierro, Madrid, Spain, ²³Reumatología, Hospital de Basurto, Basurto, Spain, ²⁴Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ²⁵Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain
Background/Purpose: Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Immunosuppression, comorbidities, and the disease itself makes patients with SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].